Over 30 types of anti-LAG-3 antagonists have progressed to the clinical development and trial phase for treating hematological tumors, breast cancer, renal cell carcinoma, melanoma, colon cancer, and other tumors (20). This evidence concerns the gene LAG3 and breast carcinoma.